These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 30258442)

  • 21. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
    Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
    Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Shi Z; Du Q; Chen H; Zhang Y; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
    J Neurol; 2020 Apr; 267(4):913-924. PubMed ID: 31776721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    Songwisit S; Kosiyakul P; Jitprapaikulsan J; Prayoonwiwat N; Ungprasert P; Siritho S
    Sci Rep; 2020 Oct; 10(1):16727. PubMed ID: 33028926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
    Kim SH; Hyun JW; Joung A; Park EY; Joo J; Kim HJ
    Mult Scler; 2017 Dec; 23(14):1902-1908. PubMed ID: 28080220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder.
    Zhou Y; Zhong X; Shu Y; Cui C; Wang J; Wang Y; Li X; Chen Z; Peng L; Kermode A; Qiu W
    Mult Scler Relat Disord; 2019 Feb; 28():213-220. PubMed ID: 30623860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study.
    Paolilo RB; Hacohen Y; Yazbeck E; Armangue T; Bruijstens A; Lechner C; Apostolos-Pereira SL; Martynenko Y; Breu M; de Medeiros Rimkus C; Wassmer E; Baumann M; Papetti L; Capobianco M; Kornek B; Rostásy K; da Paz JA; Ciccarelli O; Lim M; Saiz A; Neuteboom R; Marignier R; Hemingway C; Sato DK; Deiva K
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32732259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the treatment of neuromyelitis optica.
    Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
    J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders.
    Li X; Mei S; Gong X; Zhou H; Yang L; Zhou A; Liu Y; Li X; Zhao Z; Zhang X
    BMC Neurol; 2017 Jul; 17(1):130. PubMed ID: 28679367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Akatani R; Chihara N; Koto S; Mori S; Kurimoto T; Nakamura M; Tachibana H; Otsuka Y; Ueda T; Omori T; Sekiguchi K; Matsumoto R
    Immunol Med; 2024 Jun; 47(2):85-92. PubMed ID: 38235761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica.
    Burt RK; Balabanov R; Han X; Burns C; Gastala J; Jovanovic B; Helenowski I; Jitprapaikulsan J; Fryer JP; Pittock SJ
    Neurology; 2019 Oct; 93(18):e1732-e1741. PubMed ID: 31578302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S; Wong AH; Quek AM; Yuki N
    J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder.
    Lin J; Xue B; Li J; Zhu R; Pan J; Chen Z; Zhang X; Li X; Xia J
    Front Neurol; 2022; 13():891064. PubMed ID: 35599732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
    Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
    Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.